New trial
Phase 1 ZE50-0134 Investigational BCL‑2 Inhibitor in Relapsed Lymphoid Malignancies
- Trial ID
- NCT06708897 on ClinicalTrials.gov
- Cancer type
- Other Hematologic and Lymphoid Malignancies
- Stage of research
- First-in-human
- Location
- 4 Locations
- Published in
- New in Oncology - Aug 15, 2025 (DOUBLE ISSUE)
This trial by Eilean Therapeutics evaluates ZE50-0134, a novel BCL‑2 inhibitor, for safety, pharmacokinetics, and preliminary efficacy in patients with relapsed and refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and select low‐grade lymphomas. The study employs a multi‐part design with dose escalation and expansion arms to determine recommended doses, representing a first‑in‑human assessment in these resistant lymphoid malignancies.
More in lymphoma
-
Trial result · Oct 22, 2026 · NCT04245839
Liso-cel (CD19 CAR-T) Delivers 100% CR/ORR With Minimal CRS/Neurotoxicity in Japanese R/R FL -
Trial result · Oct 22, 2026 · NCT05800366
Glofitamab (CD3×CD20) + pola-R-CHP (CD79b ADC + anti-CD20 chemoimmunotherapy) drives 95% CR and 95% 24‑mo PFS in high-risk 1L DLBCL -
Trial result · Oct 15, 2026 · NCT03618550
Pembrolizumab-GVD followed by autologous transplantation shows 91% five-year PFS in relapsed/refractory classical Hodgkin lymphoma -
Trial result · Oct 15, 2026 · NCT03598608
Favezelimab (anti–LAG-3) + pembrolizumab (PD-1) reports 83% ORR in PD-1–naive R/R cHL; development discontinued -
Trial result · Oct 1, 2026
Mosunetuzumab (CD20xCD3 bispecific) + response-adapted polatuzumab vedotin (CD79b ADC) drives 86% PET-CR and 89% 2y PFS in untreated indolent NHL